---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-203837"
form_type: "8-K"
ticker: null
cik: "0001828522"
company_name: "eFFECTOR Therapeutics, Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:20:11.486925+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# eFFECTOR Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq letter on July 31, 2023; common stock bid price below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until January 29, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant by Jan 29, 2024, may be eligible for an additional 180-day period if other listing standards are met.
- Stock continues trading on Nasdaq Capital Market under symbol EFTR during the cure period.
- Company will monitor bid price and consider options, including a potential reverse stock split.

## SEC filing metadata
- accession: 0001193125-23-203837
- form_type: 8-K
- cik: 0001828522
- company_name: eFFECTOR Therapeutics, Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000119312523203837/0001193125-23-203837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000119312523203837/d543614d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-203837
- JSON: https://secwatch.observer/filing/0001193125-23-203837.json
- Plain text: https://secwatch.observer/filing/0001193125-23-203837.txt

## Key facts
- Listing & Compliance Notices
  eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 31, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 29, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312523203837/0001193125-23-203837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.